Health benefits and costs of screening for colorectal cancer in people on dialysis or who have received a kidney transplant

Nephrology Dialysis Transplantation

Volumn 28, Issue 4, 2013, Pages 917-926

  Wong, Germaine ^a,b,c   Li, Margaret W Y ^a   Howard, Kirsten ^b   Hua, Danny K ^a   Chapman, Jeremy R ^c   Bourke, Michael ^a   Turner, Robin ^b   Tong, Allison ^a,b   Craig, Jonathan C ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

chronic kidney disease; colorectal cancer screening; cost effectiveness; cost utility; kidney transplantation

Indexed keywords

ADULT; ARTICLE; CANCER STAGING; CHRONIC KIDNEY DISEASE; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; EARLY DIAGNOSIS; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEMODIALYSIS PATIENT; HIDDEN MARKOV MODEL; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OCCULT BLOOD; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; SENSITIVITY ANALYSIS;

AGED; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SURVIVAL RATE;

EID: 84875994284     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs490     Document Type: Article

References (56)

1. National Cancer Institute. Surveillance Epidemiology and End Results Stat Fact Sheets: Colon and Rectum Cancer. http://seer. cancer.gov/statfacts/html/ colorect.html
2. Australian Government Australian Institute of Health and Welfare (AIHW). Cancer Incidence Data Cubes. 2005; http://www.aihw.gov.au/cancer/data/datacubes/ index.cfm (6 December 2010, date last accessed
3. O'Leary BA, Olynyk JK, Neville AM et al. Cost-effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy. J Gastroenterol Hepatol 2004; 19: 38-47 (Pubitemid 38130605)
4. Launoy GD, Bertrand HJ, Berchi C et al. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population. Int J Cancer 2005; 115: 493-496 (Pubitemid 40663756)
5. Zhu MM, Xu XT, Nie F et al. Comparison of immunochemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: a meta-analysis. J Dig Dis 2010; 11: 148-160
6. Hardcastle JD, Chamberlain JO, Robinson MHE et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472-1477 (Pubitemid 26400242)
7. Hewitson P, Glasziou P, Watson E et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (Hemoccult): an update. Am J Gastroenterol 2008; 103: 1541-1549 (Pubitemid 351813919)
8. Kronborg O, Fenger C, Olsen J et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467-1471 (Pubitemid 26400241)
9. Mandel JS, Bond JH, Church TR et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993; 328: 1365-1371 (Pubitemid 23131388)
10. Quintero E, Castells A, Bujanda L et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012; 366: 697-706
11. Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg 2008; 95: 1029-1036
12. Almog R. The public prefers fecal occult blood test over colonoscopy for colorectal cancer screening. Eur J Cancer Prev 2008; 17: 430-437
13. Hawley ST, Volk RJ, Krishnamurthy P et al. Preferences for colorectal cancer screening among racially/ethnically diverse primary care patients. Med Care 2008; 46: S10-S6 doi: 10.1097/MLR.0b013e31817d932e.
14. Saeed F, Agrawal N, Greenberg E et al. Lower gastrointestinal bleeding in chronic hemodialysis patients. Int J Nephrol 2011;2011:Article ID 272535, 8 pages, doi:10.4061/2011/272535
15. Zuckerman GR, Cornette GL, Clouse RE et al. Upper gastrointestinal bleeding in patients with chronic renal failure. Ann Int Med 1985; 102: 588-592 (Pubitemid 15120474)
16. Hiremath S, Holden RM, Fergusson D et al. Antiplatelet medications in hemodialysis patients: a systematic review of bleeding rates. Clin J Am Soc Nephrol 2009; 4: 1347-1355
17. Heher EC, Thier SO, Rennke H et al. Adverse renal and metabolic effects associated with oral sodium phosphate bowel preparation. Clin J Am Soc Nephrol 2008; 3: 1494-1503
18. Wechsler A, Schneider R, Sapojnikov M et al. Bowel cleansing in patients with chronic renal failure-an often overlooked hazard. Nephrol Dial Transplant 2006; 21: 1133-1134
19. Wong G, Howard K, Craig JC et al. Cost-effectiveness of colorectal cancer screening in renal transplant recipients. Transplantation 2008; 85: 532-541
20. Kiberd BA. Screening for prostate, breast and colorectal cancer in renal transplant recipients. Am J Transplant 2003; 5: 619-625 (Pubitemid 36612846)
21. Australian and New Zealand Dialysis and Transplant Registry. The 33rd Annual Report. Adelaide: ANZDATA Registry, 2010
22. Vajdic CM, McDonald SP, McCredie MRE et al. Cancer incidence before and after kidney transplantation. JAMA 2006; 296: 2823-2831 (Pubitemid 44969182)
23. Mandel JS, Church TR, Ederer F et al. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999; 91: 434-437 (Pubitemid 29128279)
24. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96: 1420-1425 (Pubitemid 39429665)
25. Gunderson LL, Sosin H, Levitt S. Extrapelvic colon-areas of failure in a reoperation series: Implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1985; 11: 731-741 (Pubitemid 15086896)
26. Lee YTM. Local and regional recurrence of carcinoma of the colon and rectum: I. Tumour-host factors and adjuvant therapy. Surg Oncol 1995; 4: 283-293
27. Sargent DJ, Wieand HS, Haller DG et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20 898 patients on 18 randomized trials. J Clin Oncol 2005; 23: 8664-8670 (Pubitemid 46211509)
28. Wong G, Howard K, Chapman J et al. How do people with chronic kidney disease value cancer-related quality of life? Nephrology 2012; 17: 32-41
29. Australian Government National Health and Medical Research Council. Clinical Practice Guidelines for the Prevention, Early Detection and Management of Colorectal Cancer, 2005 [3]; 32-
30. http://www.nhmrc.gov.au/guidelines/publications/cp106
31. Australian Government Australian Institute of Health and Welfare (AIHW). Australian Refined Diagnosis Related Groups Data Cubes from 1998-99 to 2007-08, Version 5.0/5.1. http://www.aihw.gov.au/hospitals/datacubes/datacube-ardrg.cfm (6 December 2010, date last accessed
32. Australian Government Department of Health and Ageing. Medicare Benefits Schedule Book. Canberra ACT: AIHW, 2006.
33. Cancer Institute NSW. eviQ Cancer Treatments Online-Colorectal Chemotherapy Protocols. https://www.eviq.org.au/Category/tabid/65/categoryid/ 328/Default.aspx (20 December 2010, date last accessed
34. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001; 10: 779-787 (Pubitemid 34041389)
35. Anavekar NS, Pfeffer MA. Cardiovascular risk in chronic kidney disease. Kidney Int 2004; 66(Suppl 92): S11-S15
36. Foley RN, Parfrey PS, Samak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9 (12 Suppl): S16-S23
37. Batabyal. ea. Clinical practice guidelines on waitlisting for kidney transplantation: consistent and equitable? Transplantation 2012; 94: 703-713
38. Sawhney MS, McDougall H, Nelson DB et al. Fecal occult blood test in patients on low-dose aspirin, warfarin, clopidogrel, or non-steroidal anti-inflammatory drugs. Dig Dis Sci 2010; 55: 1637-1642
39. Levi Z, Rozen P, Hazazi R et al. Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants. Am J Gastroenterol 2009; 104: 933-938
40. Brenner H, Tao S, Haug U. Low-dose aspirin use and performance of immunochemical fecal occult blood tests. JAMA 2010; 304: 2513-2520
41. Bini EJ, Kinkhabwala A, Goldfarb DS. Predictive value of a positive fecal occult blood test increases as the severity of CKD worsens. Am J Kidney Dis 2006; 48: 580-586 (Pubitemid 44402838)
42. Akmal M. The prevalence and significance of occult blood loss in patients with predialysis advanced chronic renal failure (CRF), or receiving dialytic therapy. Clin Nephrol 1994; 42: 198-202 (Pubitemid 24287756)
43. Robinson MHE, Hardcastle JD, Moss SM et al. The risks of screening: data from the Nottingham randomised controlled trial of faecal occult blood screening for colorectal cancer. Gut 1999; 45: 588-592 (Pubitemid 29447830)
44. Winawer SJ, Zauber AG, Ho MN et al. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 1993; 329: 1977-1981 (Pubitemid 24015040)
45. Quintero E. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012; 366: 697-706
46. Williams NC, Tong A, Howard K et al. Knowledge, beliefs and attitudes of kidney transplant recipients regarding their risk of cancer. Nephrology 2012; 17: 300-306
47. Howell M, Tong A, Wong G et al. Important outcomes for kidney transplant recipients: a nominal group and qualitative study. Am J Kidney Dis 2012; 60: 186-196
48. Australian Government Australian Institute of Health and Welfare (AIHW). National Bowel Cancer Screening Program: annual monitoring report 2009 data supplement 2010. 2010 http://www.aihw.gov.au/publications/index.cfm/title/12136 (14 December 2010, date last accessed
49. Bauer FW, Robbins SL. An autopsy study of cancer patients. JAMA 1972; 221: 1471-1474
50. Burton EC, Troxclair DA, Newman WP. Autopsy diagnoses of malignant neoplasms. JAMA 1998; 280: 1245-1248
51. Papaconstantinou HT, Sklow B, Hanaway MJ et al. Characteristics and survival patterns of solid organ transplant patients developing & lt;i& gt;De Novo& lt;/i& gt; colon and rectal cancer. Dis Colon Rectum 2004; 47: 1898-1903 (Pubitemid 40064434)
52. Buell JF, Papaconstantinou HT, Skalow B et al. De novo colorectal cancer: five-year survival is markedly lower in transplant recipients compared with the general population. Transplant Proc 2005; 37: 960-961 (Pubitemid 40590759)
53. Lüning T, Keemers-Gels M, Barendregt W et al. Colonoscopic perforations: a review of 30 366 patients. Surg Endosc 2007; 21: 994-997 (Pubitemid 47055793)
54. Mai C-M, Wen C-C, Wen S-H et al. Iatrogenic colonic perforation by colonoscopy: a fatal complication for patients with a high anesthetic risk. Int J Colorectal Dis 2010; 25: 449-454
55. Jansman FGA, Postma MJ, van Hartskamp D et al. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Clin Ther 2004; 26: 579-589 (Pubitemid 38586459)
56. Cass A, Chadban S, Craig J et al. The Economic Impact of End-Stage Kidney Disease in Australia. Sydney: The George Institute, 2006